Svs Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.42 M
as on 16-11-2024
- Company Age 40 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.93 M
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit -30.41%
(FY 2023)
- Ebitda -30.55%
(FY 2023)
- Net Worth -1.49%
(FY 2023)
- Total Assets -1.50%
(FY 2023)
About Svs Drugs And Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.42 M.
The company currently has active open charges totaling ₹2.93 M.
Bandi Vamsikrishna and Chandra Tumuluru serve as directors at the Company.
- CIN/LLPIN
U24230TG1984PTC004422
- Company No.
004422
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jan 1984
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Svs Drugs And Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bandi Vamsikrishna  | Director | 12-Nov-2009 | Current |
| Chandra Tumuluru | Director | 18-Feb-2016 | Current |
Financial Performance of Svs Drugs And Pharmaceuticals.
Svs Drugs And Pharmaceuticals Pvt Ltd, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 30.41% decrease in profit. The company's net worth dipped by a decrease of 1.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Svs Drugs And Pharmaceuticals?
In 2023, Svs Drugs And Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hetero Marbles Private LimitedActive 27 years 6 monthsBandi Vamsikrishna and Chandra Tumuluru are mutual person
- Hetero Biopharma LimitedActive 8 years 3 months
Bandi Vamsikrishna and Chandra Tumuluru are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Andhra Pradesh State Financial Corp. Creation Date: 18 Mar 1986 | ₹2.93 M | Open |
How Many Employees Work at Svs Drugs And Pharmaceuticals?
Unlock and access historical data on people associated with Svs Drugs And Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Svs Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Svs Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
